GlycoDiagnostics aims to detect people with potentially dangerous liver disease early on, before it is too late.

Millions of people suffer from fatty liver disease, which can develop into a progressive inflammation and fibrosis, a silent condition that often goes undiagnosed until it’s too late. Current tests are invasive, unreliable, or hard to access. That’s why they are developing a simple, non-invasive blood test based on a unique glycan biomarker discovered at Leiden University Medical Center. Theirtest is designed to catch liver fibrosis early, especially in high-risk groups like people with type 2 diabetes, so that healthcare providers can take action sooner to slow or stop disease progression. Early detection means better outcomes, lower healthcare costs, and a healthier future.